Barclays
TCRT icon

Barclays’s Alaunos Therapeutics TCRT Stock Holding History

Barclays’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,946
Closed -$3.17M – 6969
2016
Q4 		$3.17M Buy
+3,946
New +$3.56M ﹤0.01% 1743
2015
Q2 		– Sell
-3,401
Closed -$5.1M – 7194
2015
Q1 		$5.1M Buy
+3,401
New +$5.04M 0.01% 1545

Other funds holding TCRT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
EverSource Wealth Advisors
EverSource Wealth Advisors Birmingham, Alabama $3.11B AUM 21.48% 1-Year Est. Return
BOK Financial
BOK Financial Tulsa, Oklahoma $6.69B AUM 26.84% 1-Year Est. Return
Key Financial Inc
Key Financial Inc West Chester, Pennsylvania $614M AUM 14.43% 1-Year Est. Return
SignatureFD
SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return
Newbridge Financial Services Group
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return
NBC Securities
NBC Securities Birmingham, Alabama $1.47B AUM 20.38% 1-Year Est. Return
West Paces Advisors
West Paces Advisors Atlanta, Georgia $586M AUM 14.12% 1-Year Est. Return
Inspire Investing
Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return
IFG Advisory
IFG Advisory Atlanta, Georgia $3.01B AUM 18.54% 1-Year Est. Return

Barclays's TCRT Position: Q3 2026 in Review

Barclays sold out of Alaunos Therapeutics (TCRT) in Q3 2026, closing a stake of 15 shares — an estimated $34 sold.

Barclays first reported a position in TCRT in Q2 2013 and held it in 41 quarters. The position peaked at $5.59M in Q4 2013. 12 funds tracked by Wall St. Rank hold TCRT as of Q3 2026.

  • Barclays reported no remaining Alaunos Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Barclays sold 15 Alaunos Therapeutics shares in Q3 2026, an estimated $34.
  • Barclays first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 41 quarters.
  • Barclays's Alaunos Therapeutics position peaked at $5.59M in Q4 2013.
  • 12 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.